Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Merck to Begin Arbitration With J & J

September 8, 2010 7:40 am | by Linda A. Johnson | News | Comments

Drugmaker Merck & Co. said that arbitration will begin in late September in its dispute with Johnson & Johnson over revenue from two blockbuster drugs for rheumatoid arthritis and other immune disorders.


BMS Set to Buy ZymoGenetics for $885M

September 8, 2010 7:37 am | by Marley Seaman | News | Comments

Bristol-Myers Squibb Co. said it will acquire biotechnology partner ZymoGenetics Inc. for $885 million in another move by a major drugmaker to boost its pipeline by snapping up a smaller developer.


Abbott Acquires Second-Largest Pharma in India

September 8, 2010 7:35 am | News | Comments

Abbott has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian pharmaceutical market and further accelerating the company's growth in emerging markets.


UV Monitoring Accessory

September 7, 2010 8:41 am | Product Releases | Comments

CEM Corporation, a leading global provider of microwave laboratory instrumentation, has announced the introduction of its UV Monitoring System, which is designed to work with CEM’s Liberty and Liberty1 Microwave Peptide Synthesizers.


Gel Documentation System

September 7, 2010 8:39 am | Product Releases | Comments

Bio-Rad Laboratories announced the launch of the Gel Doc EZ, a compact gel documentation system that provides publication-quality images and analysis in seconds — with just the push of a button.


Grifols Using West Technology For Coagulation Therapies

September 7, 2010 8:35 am | News | Comments

West, a premier manufacturer of components and systems for injectable drug delivery, and Grifols USA, LLC announced the availability of West’s Mix2Vial filtered transfer system for the reconstitution of Grifols’ coagulation therapies.


Emerald And SomaLogic Begin Design Collaboration

September 7, 2010 8:30 am | News | Comments

Emerald BioStructures and SomaLogic, Inc. announced that they have entered into a strategic collaboration for the structure-based design of chemically modified DNA aptamers and small molecule therapeutics, based on crystal structures of important protein targets bound to high affinity SOMAmers.


New Treatment Activates Cell Death In Cancer

September 7, 2010 8:26 am | News | Comments

Conventional chemotherapy employs treatment with one or more drugs, assuming that these medicines are able to both "diagnose" and "treat" the affected cells. Many of the side effects experienced by chemotherapy patients are due to the fact that the drugs they are taking aren't selective enough.


Magic Mushrooms A Promising Mood Elevator

September 7, 2010 8:22 am | News | Comments

A pilot study suggests the hallucinogen psilocybin may be feasible and safe to administer to patients with advanced-stage cancer and anxiety, with promising effects on mood.


Promedior Begins Phase 2a Trial of PRM-151

September 7, 2010 8:17 am | News | Comments

Promedior, Inc. has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery.


Orexigen Signs Billion Dollar Deal With Takeda

September 7, 2010 8:14 am | News | Comments

Orexigen Therapeutics Inc. has signed a $1 billion co-development agreement for its experimental obesity drug Contrave with Takeda Pharmaceuticals. Under the deal, Orexigen will receive $50 million upfront from Takeda, Japan's largest drugmaker.


Abbott Halts Influvac Sale

September 7, 2010 8:11 am | by Matthew Perrone | News | Comments

Drug and medical device firm Abbott Laboratories said it has abandoned plans to sell its vaccines unit, less than three months after exploring sales talks with rival companies.


Blood Pressure Medicine Not Always Suited to User

September 7, 2010 8:02 am | by Lauran Neergard | News | Comments

It's hard to predict which pills will best lower which patient's high blood pressure, but researchers are hunting ways to better personalize therapy - perhaps even using a blood test. The work is controversial, challenging today's usual approach to treating the hypertension that plagues nearly one in three U.S. adults.


Bone-Strengthening Drug May Raise Risk of Cancer

September 7, 2010 7:57 am | by Maria Cheng | News | Comments

People who take bone-strengthening drugs for several years may have a slightly higher risk of esophageal cancer, a new study suggests. The findings are in contrast to another recent study that used the same database of 80,000 patients and found no link between the drugs and esophageal cancer.


WHO Wants Faster Flu Vaccine Production

September 7, 2010 7:54 am | News | Comments

The vaccine used to contain the recent swine flu pandemic was effective, but health authorities will need to ramp up the speed and volume of production during the next global outbreak, a World Health Organization official said.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.